Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIAO for Thrombocytopenia in Chronic Liver Disease
NCT05193201Phase 1Unknown
- Sponsor
- 3SBio
- Start
- Jan 2022
- Primary completion
- Oct 2022
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant human thrombopoietin in Thrombocytopenia (2 cohorts), sponsored by 3SBio. Primary endpoint: Proportion of responders with platelet count at 8 days. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT05193201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193201.